Skip to Content

CRISPR Therapeutics AG CRSP Stock Quote

| Rating as of

NASDAQ: CRSP

Market Closed

| Currency in USD

  • Last Close 45.49
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Mid Growth
  • Day Range 45.47  –  46.95
  • Year Range 38.94  –  72.00
  • Market Cap 3.6124 Bil
  • Volume / Avg 660,112.0 /  948,839.2
  • Price / Sales 21.00
  • Price / Book 1.99
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis CRSP

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Positive Outlook for CRISPR Therapeutics' Gene Editing Technology; Shares Very Undervalued

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

CRISPR Therapeutics is a clinical-stage gene editing company focused on the development of CRISPR/Cas9-based therapeutics. The company's proprietary platform specializes in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR’s emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CRSP

Company Profile CRSP

Business Description

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Contact
Baarerstrasse 14
Zug, CH-6300, CHE
Industry Biotechnology
Employees 458

Related Articles CRSP

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of CRSP’s competitive advantage.

CRISPR Therapeutics AG

XNAS: CRSP

Vertex Pharmaceuticals Inc

XNAS: VRTX

Moderna Inc

XNAS: MRNA

BioNTech SE ADR

XNAS: BNTX
Price
45.49349.5399.99104.64
Currency
USDUSDUSDUSD
Change
−$0.57 (1.24%) −$4.75 (1.34%) −$0.24 (0.24%) −$1.79 (1.68%)
Market Cap
3.61 Bil90.21 Bil38.06 Bil25.09 Bil
Industry
Biotechnology Biotechnology Biotechnology Biotechnology
Sector
Healthcare
Healthcare
Healthcare
Healthcare

* Trading data in this section is delayed by at least 15 minutes.

FAQs for CRISPR Therapeutics AG Stock

No. CRSP does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CRSP’s market cap is 3.61 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CRSP’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CRSP’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CRSP’s historical performance against its industry peers and the overall market.